Abstract:By searching the literatures, it was found that a total of 32 drugs interacting with herbal medicines in humans. These drugs mainly include anticoagulants (warfarin, aspirin and phenprocoumon), sedatives and antidepressants (midazolam, alprazolam and amitriptyline), oral contraceptives, anti-HIV agents (indinavir, ritonavir and saquinavir), cardiovascular drug (digoxin), immunosuppressants (cyclosporine and tacrolimus) and anticancer drugs (imatinib and irinotecan). Most of them are substrates for cytochrome P450s (CYPs) and/or P-glycoprotein (PgP) and many of which have narrow therapeutic indices. However, several drugs including acetaminophen, carbamazepine, mycophenolic acid, and pravastatin did not interact with herbs. Both pharmacokinetic (e.g. induction of hepatic CYPs and intestinal PgP) and/or pharmacodynamic mechanisms (e.g. synergistic or antagonistic interaction on the same drug target) may be involved in drug-herb interactions, leading of altered drug clearance, response and toxicity. Toxicity arising from drug-herb interactions may be minor, moderate, or even fatal, depending on a number of factors associated with the patients, herbs and drugs. Predicting drug-herb interactions, timely identification of drugs that interact with herbs, and therapeutic drug monitoring may minimize toxic drug-herb interactions. It is likely to predict pharmacokinetic herb-drug interactions by following the pharmacokinetic principles and using proper models that are used for predicting drug-drug interactions. Identification of drugs that interact with herbs can be incorporated into the early stages of drug development. A fourth approach for circumventing toxicity arising from drug-herb interactions is proper design of drugs with minimal potential for herbal interaction. So-called ”hard drugs” that are not metabolized by CYPs and not transported by PgP are believed not to interact with herbs due to their unique pharmacokinetic properties. More studies are needed and new approached are required to minimize toxicity arising from drug-herb interactions. Keywords: Drug-herb interaction, Drug design, Herbs, Cytochrome P450, P-glycoprotein

[Drug interactions on P-glycoprotein transport level and its application]

The Effects of Traditional Chinese Medicine on P-Glycoprotein–Mediated Multidrug Resistance and Approaches for Studying the Herb–P-Glycoprotein Interactions

Drug-drug interactions mediated by p-glycoprotein

Inhibitory Effects of Herbal Constituents on P-glycoprotein in Vitro and in Vivo: Herb-Drug Interactions Mediated Via P-gp.

Effects of P-glycoprotein on the Pharmacokinetics and Interaction Mediated by P-glycoprotein

Investigation on Modulation of Human Cytochrome P450 and P-glycoprotein by Herb or Natural Product Using in Vivo Probe Substrate

Research Progress on P-glycoprotein-mediated Drug Interactions

Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In Vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein

Advances in Pharmacokinetic Mechanisms of Transporter-Mediated Herb-Drug Interactions

20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro And In Vivo: A Case For Herb-Drug Interactions

Progress in Search for Interactions Between P-glycoprotein and Central Depressants

Progress in Clinical Herb-Drug Interactions Mediated by Drug Metabolism- Related Genes

Ginsenoside Metabolites Inhibit P-Glycoprotein in Vitro and in Situ Using Three Absorption Models

Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure-activity relationships

Research Advance on P-glycoprotein Inhibitors and the Structure-Activity Relationship

Translational Research Insights into Pharmacokinetic Herb-Drug Interactions

Synergistic effect of CYP3A and P-glytoprotein on the first-pass effect of drugs in the intestine

P-glycoprotein Mediated Drug-Drug Interaction of Central Nervous System Drugs

Functional interactions between P-glycoprotein and CYP3A in drug metabolism

Drug-herb Interactions: Eliminating Toxicity with Hard Drug Design.

Transporter modulation by Chinese herbal medicines and its mediated pharmacokinetic herb-drug interactions